Immunic CEO Highlights New York MS R&D Day and Vidofludimus Calcium in MS Studies

2 min read | September 13, 2024 04:33 AM PDT | By Team Kalkine Media

Google News:

Immunic CEO Highlights New York MS R&D Day and Vidofludimus Calcium in MS Studies — Image source: Shutterstock

Recent News

Why The Small-Cap Drug Story Quietly Drawing Attention?

What’s Driving Interest In Gorman-Rupp’s Small Cap Story?

Target Navigates A Balancing Act As Retail Shifts

Why This Everyday Giant Stays at the Center of Retail?

Make Kalkine Media
My Trusted Source

Immunic Inc (NASDAQ:IMUX) recently provided an update on its progress in developing vidofludimus calcium, a promising treatment for multiple sclerosis (MS). CEO Daniel Vitt shared insights into the company's advancements during an interview with Proactive, following the company’s MS R&D Day held in New York.

Vidofludimus calcium is positioned as a key therapeutic agent for managing all forms of MS. The drug operates as a Nurr1 activator, which is instrumental in addressing neuroprotection for MS patients. This mechanism of action is central to its anticipated efficacy in treating MS.

Vitt discussed the drug's potential to impact both relapsing and progressive forms of MS. He underscored a crucial aspect of MS management: the progression of disability in MS patients can occur independently of relapses. Vidofludimus calcium aims to meet this significant unmet need by offering a broad-spectrum treatment solution.

Immunic Inc's ongoing research includes several key upcoming milestones. An interim futility analysis from the ENSURE phase 3 study in relapsing MS is anticipated, along with results from the phase 2 CALLIPER study in progressive MS, expected next April. These data points are highly anticipated as they will provide further insights into the drug's efficacy and potential for widespread use.

In the broader context of the healthcare sector, Immunic Inc's efforts reflect a significant push towards addressing chronic and complex conditions such as MS. The company's focus on advancing innovative therapies aligns with the ongoing evolution in healthcare, where new treatments are continually being developed to better manage and potentially alter the course of various diseases.

As the healthcare landscape evolves, companies like Immunic Inc are at the forefront, working to bring forward new solutions that address critical medical needs. The development of vidofludimus calcium exemplifies the commitment to enhancing patient outcomes through innovative research and development.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.